What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Surgery, Oncology, Sunitinib and Carcinoma.
Much of his study explores Internal medicine relationship to Gastroenterology.
His study in Surgery is interdisciplinary in nature, drawing from both Hazard ratio and Urology.
His Oncology research is multidisciplinary, relying on both Clinical trial, Immunology and FOXP3.
Stephane Oudard works mostly in the field of Sunitinib, limiting it down to topics relating to Temsirolimus and, in certain cases, Pazopanib, as a part of the same area of interest.
His studies in Docetaxel integrate themes in fields like Cabazitaxel, Mitoxantrone and Clinical endpoint.
His most cited work include:
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (4612 citations)
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer (4473 citations)
- Sorafenib in advanced clear-cell renal-cell carcinoma. (4025 citations)
What are the main themes of his work throughout his whole career to date?
Stephane Oudard mainly investigates Internal medicine, Oncology, Prostate cancer, Renal cell carcinoma and Docetaxel.
His Internal medicine study frequently draws connections to adjacent fields such as Surgery.
His Surgery study combines topics from a wide range of disciplines, such as Gastroenterology and Urology.
As a part of the same scientific study, Stephane Oudard usually deals with the Oncology, concentrating on Hazard ratio and frequently concerns with Proportional hazards model.
His Docetaxel study combines topics in areas such as Mitoxantrone, Toxicity and Prednisone.
The various areas that Stephane Oudard examines in his Sunitinib study include Kidney cancer and Tyrosine-kinase inhibitor.
He most often published in these fields:
- Internal medicine (73.38%)
- Oncology (63.88%)
- Prostate cancer (30.04%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (73.38%)
- Oncology (63.88%)
- Prostate cancer (30.04%)
In recent papers he was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Prostate cancer, In patient and Castration resistant.
His study in Renal cell carcinoma, Nivolumab, Cohort, Chemotherapy and Clinical endpoint is carried out as part of his Internal medicine studies.
His study in Oncology focuses on Sunitinib in particular.
His work in Prostate cancer addresses subjects such as Progression-free survival, which are connected to disciplines such as Randomized controlled trial.
As part of the same scientific family, Stephane Oudard usually focuses on Castration resistant, concentrating on Poor prognosis and intersecting with CATS and Clinical progression.
His work carried out in the field of Docetaxel brings together such families of science as Biomarker and Febrile neutropenia.
Between 2017 and 2021, his most popular works were:
- Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer (452 citations)
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial (204 citations)
- Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal (194 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Chemotherapy
His primary areas of investigation include Internal medicine, Oncology, Prostate cancer, Androgen deprivation therapy and Renal cell carcinoma.
He does research in Oncology, focusing on Sunitinib specifically.
The various areas that he examines in his Prostate cancer study include Metastasis and Disease.
His biological study spans a wide range of topics, including Everolimus and Microphthalmia.
His research investigates the connection between Everolimus and topics such as Tolerability that intersect with problems in Kidney cancer.
Stephane Oudard interconnects Febrile neutropenia and Cabazitaxel in the investigation of issues within Docetaxel.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
